Thank you for registering with Pulmonary Fibrosis New’s Clinical Trial Registry.
We will inform you of new clinical trials as information becomes available.
In the meantime, feel free to access these other PF-related resources:
Ofev News:
- Fatigue Weights on IPF Patients and Tends to Worsen Over Time, Study Finds
- GLPG1205 Safely Eases Lung Function Decline in IPF Patients, Phase 2 Trial Shows
- 1st Patient Enrolled in Trial Testing Ofev on Post-COVID-19 PF
- Esbriet or Ofev Reduce Inflammatory and Oxidative Stress Markers in IPF, Small Study Shows
- Ofev, Esbriet Use Seen to Lengthen Life for IPF Patients With ‘Mild’ Disease
- Pamrevlumab May Be More Effective in IPF Than Esbriet and Ofev, Study Suggests
- Experimental Peptide Combined With Ofev Reduced IPF Symptoms in Mice
IPF News:
- Dosing Begins in 2nd Phase 3 Trial of Antibody Treatment for IPF
- Phase 2 Trial of C21, Potential Oral Therapy for IPF, Opens
- Procalcitonin Blood Levels May Help Detect Lung Cancer in IPF Patients, Study Suggests
- Biognosys, Boehringer Ingelheim Partner for Protein Studies of IPF
- World’s First Single-cell Sequencing Atlas Available for Drug Discovery in IPF
- IPF Hospitalizations, Mortality Rate Seen to Drop in US from 2006-16
- Algernon’s NP-120 Surpasses Merck’s MK-7264 in Reducing Cough Frequency in Animal Model of Acute Cough, Study Shows
Esbriet News:
- Fatigue Weights on IPF Patients and Tends to Worsen Over Time, Study Finds
- GLPG1205 Safely Eases Lung Function Decline in IPF Patients, Phase 2 Trial Shows
- Potential IPF Treatment, LYT-100, Shows Good Tolerability in Trial
- Esbriet or Ofev Reduce Inflammatory and Oxidative Stress Markers in IPF, Small Study Shows
- Ofev, Esbriet Use Seen to Lengthen Life for IPF Patients With ‘Mild’ Disease
- Pamrevlumab May Be More Effective in IPF Than Esbriet and Ofev, Study Suggests
- Trial to Test Higher Dose of Inhaled Pirfenidone in All Participants
CPF News:
- Evel Knievel: Dedicated to Defying Death, Lost To IPF
- PFF Brings Daughters of PF Program Under Its Wings
- CPF Names 2014 Most Important Year for Pulmonary Fibrosis
- FDA Includes CPF Advocates in IPF Workshop
- CPF Organizing a Series of Educational Activities for the 2014 Pulmonary Fibrosis Awareness Month
- PFF and CPF Documentary About Idiopathic Pulmonary Fibrosis to Air on Discovery Channel
- Coalition for Pulmonary Fibrosis Group Leads National Pulmonary Fibrosis Month
IPF Clinical Trial News:
- UK Trial Recruiting IPF Patients to Test Nalbuphine Extended Release Tablets for Chronic Cough
- ART-123 Doesn’t Prolong Life in IPF Acute Exacerbations, Study Says
- 4 Factors that Impact Pulmonary Fibrosis Prevention
- Galecto’s Inhaled TD139 a Promising Therapy for IPF, Scottish Study Finds
- Bellerophon’s INOpulse Inhaled Nitrous Oxide Device Improves Symptoms of PH-IPF Patients, Study Finds
- Kadmon Presents Preclinical Data Supporting ROCK Inhibition as Way of Treating PF
- First Patient Enrolled in Trial of Ofev for Progressive Fibrosing Interstitial Lung Disease
FDA News:
- Treprostinil Earns FDA Orphan Drug Designation for Treating IPF
- Ofev Approved in US and Canada for Progressive Fibrosing ILDs
- FDA Names AMP945, Potential IPF Treatment, an Orphan Drug
- Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds
- FDA Efforts to Bring Patients into Treatment Decisions Focus of NORD Webinar
- NORD 2019 Rare Disease Summit Set for Oct. 21-22 in Washington, DC
- FDA Grants Orphan Drug Status to Nitric Oxide as Potential IPF Treatment